Satsuma peels off staff, cutting head count by 36% to save cash while searching for a deal

Satsuma Pharmaceuticals is hunkering down while searching for a savior. After opting against trying to commercialize a migraine candidate itself, the biotech has outlined plans to lay off 36% of its employees to eke out its cash ahead of a planned strategic transaction.